Galera Therapeutics, Inc.

OTC: GRTX · Healthcare · Biotechnology

PublicHQ Malvern, PA · ChesterCIK 0001563577Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 66DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ return on equity, return on assets · ↓ workforce scale, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

$149.0M

Employees

as of 2026-08-23

Market cap

$3.6B

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income$149.0M$149.0M2025

Operating income-$2.5M-$2.5M2025

Total assets$7.2M$7.2M2025

Liabilities$645.0k$645.0k2025

Equity$4.0M$4.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Galera Therapeutics, Inc.’s financial profile?

Galera Therapeutics, Inc. earned $149.0M in FY2025 net income.

Peers · Healthcare

Veradermics, Incorporated——Enliven Therapeutics, Inc.——Legend Biotech Corporation——Vicore Pharma Holding AB——MBX Biosciences, Inc. Common Stock——Structure Therapeutics Inc.——

Neighbors

Chester →

AMETEK, Inc.$7.4B83B+West Pharmaceutical Services, Inc.$3.1B86A Bentley Systems, Incorporated$1.5B67B CubeSmart$1.1B62C Vishay Intertechnology, Inc.$3.1B71B Ecovyst Inc.$723.5M60C

Key facts

CEOJ. Mel Sorensen

SectorHealthcare

IndustryBiotechnology

HeadquartersMalvern, PA

ExchangeOTC: GRTX

Employees3

IPO date2019-11-07

Latest filings

8-K2026-08-04 8-K2026-07-31 8-K2026-07-13 8-K2026-07-07 8-K2026-05-19 8-K2026-05-15 10-Q2026-05-14 8-K2026-05-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.